Baker McKenzie advised Basilea Pharmaceutica on all legal aspects of the this PIPE transaction. The team consisted of Matthias Courvoisier (Partner, Capital Markets - pictured left), Philip Spoerlé (Senior Associate, Capital Markets - pictured right),
Tags :Baker McKenzie
The Baker McKenzie team was led by Samuel Marbacher (Partner, Zurich - pictured left) and Martin Furrer (Partner, Zurich - pictured right) and included Charles Gschwind (Senior Associate, Zurich/Geneva), Olivier Ducrey (Partner, Geneva), Basil
The Baker McKenzie team was led by Alexander Fischer (pictured), together with Howard Wu, Alexander Blaeser, Matthias Trautmann
In a pro bono project for the Swiss National Working Group on Swiss Franc Reference Rates (NWG), Baker McKenzie prepared a Form of Amendment Agreement for Swiss law governed syndicated credit facility agreements using CHF
Prior to joining Baker McKenzie, Michael spent more than 30 years at a "Big Four" law firm in Paris, serving as a tax, compensation and benefits advisor to C-suite executives and human resources leaders at CAC 40/
Baker McKenzie has advised argenx on its strategic collaboration and exclusive license agreement with Zai Lab for the development and commercialization of efgartigimod in Greater China, including mainland China, Hong Kong, Taiwan and Macau.
The law firm advised Syndicate Banks on a sustainability-linked CHF525m syndicated credit facility agreement for dormakaba Group with SARON as Near Risk Free Rate.
Baker McKenzie acted as transaction counsel. The team was led by Matthias Courvoisier (pictured left), Alexander Wyss (pictured centred) and Yves Mauchle (pictured right)
The team was led by Matthias Courvoisier (Partner, Capital Markets - pictured left) and Philip Spoerlé (Senior Associate, Capital Markets and Banking & Finance - pictured right) and further comprised Charlotte Rüegg (Associate, Banking & Finance)
The team consisted of Samuel Marbacher (Partner Zurich, pictured left) and Daniel Kälin (Associate Zurich, pictured right).
